Biodistributions of the HER2-LsbMDDs in various organs after an IV administration were assessed compared to those for Tynen®, the LsbMDDs, and the DNS-LsbMDDs in MCF-7/HER2 tumor-bearing mice. This evidence concerns the gene ERBB2 and neoplasm.